Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134.

@article{Hashim2014TargetedPC,
  title={Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134.},
  author={Yassar M. Hashim and Dirk Spitzer and Suwanna Vangveravong and M Christine Hornick and Gunjal Garg and John R. Hornick and Peter S. Goedegebuure and Robert H. Mach and W. G. Hawkins},
  journal={Molecular oncology},
  year={2014},
  volume={8 5},
  pages={956-67}
}
Pancreatic adenocarcinoma is highly resistant to conventional therapeutics and has been shown to evade apoptosis by deregulation of the X-linked and cellular inhibitors of apoptosis proteins (XIAP and cIAP). Second mitochondria-derived activator of caspases (Smac) induces and amplifies cell death by reversing the anti-apoptotic activity of IAPs. Thus, Smac-derived peptide analogues (peptidomimetics) have been developed and shown to represent promising cancer therapeutics. Sigma-2 receptors are… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Effect of DAPK1 gene on proliferation, migration, and invasion of carcinoma of pancreas BxPC-3 cell line.

International journal of clinical and experimental pathology • 2014
View 2 Excerpts
Highly Influenced

Knockdown of AGR2 induces cell apoptosis and reduces chemotherapy resistance of pancreatic cancer cells with the involvement of ERK/AKT axis.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] • 2018
View 1 Excerpt

Similar Papers

Loading similar papers…